Welcome to our dedicated page for EVOMMUNE news (Ticker: EVMN), a resource for investors and traders seeking the latest updates and insights on EVOMMUNE stock.
Evommune, Inc. (NYSE: EVMN) is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. The Evommune news page on Stock Titan aggregates company announcements, press releases and other coverage related to its pipeline, clinical data and corporate developments.
Readers can find updates on Evommune’s lead product candidates, EVO756 and EVO301, including milestones in Phase 2 and Phase 2b clinical trials. Recent communications from the company have highlighted Phase 2 data for EVO756 in adults with chronic inducible urticaria, as well as ongoing studies in chronic spontaneous urticaria and atopic dermatitis. News items also describe the design and goals of the Phase 2 trial for EVO301 in moderate-to-severe atopic dermatitis and the exploration of additional indications such as ulcerative colitis.
In addition to clinical results and study progress, Evommune’s news includes financial and corporate updates, such as quarterly financial results, collaboration-related revenue, and details about its initial public offering and listing on the New York Stock Exchange under the symbol EVMN. These releases often discuss how the company views its capital position in relation to its development plans and upcoming clinical readouts.
Investors and followers of the pharmaceutical preparations and biotechnology sector can use this page to monitor Evommune’s disclosures about its chronic inflammatory disease programs, risk factors mentioned in forward-looking statements, and strategic collaborations. Bookmark this page to access an organized stream of Evommune-related news as the company reports on its clinical pipeline and corporate activities.
Evommune (NYSE: EVMN) entered a securities purchase agreement to sell 4,494,279 shares of common stock at $27.88 per share for gross proceeds of approximately $125 million. The private placement is expected to close on or about February 17, 2026, subject to customary conditions.
Placement agents and an advisor assisted the deal. Evommune intends to use net proceeds to advance its clinical development programs and for general corporate purposes, and agreed to file a registration statement for resale of the issued shares.
Evommune (NYSE: EVMN) reported positive top-line Phase 2a results for EVO301 in moderate-to-severe atopic dermatitis. The 70-patient trial met its Bayesian primary endpoint with 99.8% posterior success and showed statistically significant, placebo-adjusted EASI reductions of 33% at week 12.
Additional highlights: 23% of patients achieved vIGA-AD 0/1 at week 12 versus 0% placebo, favorable PK supporting Q4-week dosing, no related serious adverse events, and plans for a Phase 2b subcutaneous dose-ranging trial.
Evommune (NYSE: EVMN) reported Q3 2025 results and a business update highlighting upcoming clinical milestones and its recent IPO. The company expects three Phase 2 readouts in 2026 across lead programs EVO756 (MRGPRX2 antagonist) and EVO301 (IL-18 inhibitor), including Phase 2b top-line data in CSU in 1H26 and Phase 2a/2b AD readouts in 1H–2H26. The company completed an IPO in November 2025, raising $172.5 million gross proceeds. Q3 financials: $10.0M revenue (collaboration with Maruho), $76.0M cash and investments as of Sept 30, 2025, R&D expense of $19.6M, and net loss of $12.5M.
Evommune (NYSE:EVMN) priced its initial public offering of 9,375,000 common shares at $16.00 per share, with gross proceeds expected to be $150 million before underwriting discounts, commissions, and expenses. Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares.
The shares are expected to begin trading on the New York Stock Exchange on November 6, 2025 under ticker EVMN, and the offering is expected to close on November 7, 2025, subject to customary closing conditions.
Evommune (NYSE:EVMN) announced the commencement of a proposed initial public offering on October 17, 2025 with a registration statement filed on Form S-1.
The company is offering 9,375,000 shares of common stock with an expected price range of $15.00 to $17.00 per share, and intends to grant underwriters a 30-day option for up to 1,406,250 additional shares. Evommune has applied to list its shares on the New York Stock Exchange under the symbol EVMN, and expects the registration statement to become automatically effective on November 5, 2025 pursuant to Section 8(a) of the Securities Act, subject to SEC and federal government operations.